Pharvaris (NASDAQ:PHVS) Hits New 52-Week High – Time to Buy?

Shares of Pharvaris N.V. (NASDAQ:PHVS) hit a new 52-week high during trading on Friday . The company traded as high as $37.14 and last traded at $35.8250, with a volume of 452 shares traded. The stock had previously closed at $34.45.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. UBS Group set a $74.00 target price on shares of Pharvaris in a research note on Wednesday, May 13th. HC Wainwright reissued a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Morgan Stanley raised their price target on shares of Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Finally, Citizens Jmp dropped their price objective on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Stock Performance

The stock has a 50-day simple moving average of $33.14 and a 200 day simple moving average of $29.78. The company has a market cap of $2.30 billion, a P/E ratio of -11.00 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Sell-side analysts anticipate that Pharvaris N.V. will post -2.97 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Anna Nijdam sold 2,670 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the completion of the transaction, the insider owned 46,275 shares in the company, valued at $1,428,509.25. This trade represents a 5.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 178,322 shares of company stock worth $5,969,286. Insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Persistent Asset Partners Ltd acquired a new stake in shares of Pharvaris in the 2nd quarter valued at $273,000. GSA Capital Partners LLP acquired a new stake in shares of Pharvaris during the 2nd quarter worth about $558,000. CoreCap Advisors LLC acquired a new stake in shares of Pharvaris during the 2nd quarter worth about $93,000. Seven Fleet Capital Management LP lifted its holdings in Pharvaris by 472.3% during the 1st quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after purchasing an additional 261,355 shares during the last quarter. Finally, DV Trading LLC bought a new position in Pharvaris during the 1st quarter valued at about $4,067,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.